Decreased production of TNF-alpha by lymph node cells indicates experimental autoimmune encephalomyelitis remission in Lewis rats

Memorias do Instituto Oswaldo Cruz

Volumn 105, Issue 3, 2010, Pages 263-268

  Seger, Juliana ^a   Zorzella Pezavento, Sofia Fernanda Gonçalves ^a   Pelizon, Ana Cláudia ^a   Martins, Douglas Rodrigues ^a   Domingues, Alexandre ^a   Sartori, Alexandrina ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Alpha; Biomarkers; Experimental autoimmune encephalomyelitis; Rats inbred Lew; Tumor necrosis factor

Indexed keywords

ANIMALIA; RATTUS;

EID: 77953501973     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762010000300004     Document Type: Article

References (39)

1. Adams CW, Poston RN, Buk, SJ 1989. Pathology, histochemistry and immunocytochemistry. J Nat Sci 92: 291-306.
2. Amorini AM, Petzold, A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D'Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G 2009. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42: 1001-1006.
3. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M 2003. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Eng J Med 349: 139-145.
4. Bock T, Pakkenberg B, Buschard K 2003. Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52: 1716-1722.
5. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Young VW 2002. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297-1308.
6. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham K.A 2002. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8: 613-619.
7. Cannella B, Hoban CJ, Gao YL, Garcia-Arenas R, Lawson D, Marchionni M 1998. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc Nat Acad Sci USA 95: 10100-10105.
8. Dore-Duffy P, Balabanov R, Washington R, Swanborg RH 1994. Transforming growth factor β1 inhibits cytokine-induced CNS endothelial cell activation. Molec Chem Neuropathol 22: 161-175.
9. Fazilleau N, McHeyzer-Williams LJ, McHeyzer-Williams MG 2007. Local development of effector and memory T helper cells. Curr Opin Immunol 19: 259-267.
10. Furlan R, Brambilla E, Ruffini F, Poliani PL, Bergami A, Marconi PC, Franciotta DM, Penna G, Comi G, Adorini L, Martino G 2001. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 67: 1821-1829.
11. Gold R, Linington C, Lassmann H 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental encephalomyelitis research. Brain 129: 1953-1971.
12. Gold R, Linker RA, Chan A 2007. Termination of inflammation in the nervous system. Rev Neurol 163: 672-676.
13. Harness J, Cavanagh A, Morton H, McCombe P 2003. A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J Neurol Sci 216: 33-41.
14. Hickey WF, Gonatas NK, Kimura H, Wilson DB 1983. Identification and quantitation of T lymphocyte subsets found in the spinal cord of the Lewis rat during acute experimental allergic encephalomyelitis. J Immunol 131: 2805-2809.
15. Holmøy T, Hestvik AL 2008. Multiple sclerosis: immunopathogenesis and controversies in defining the cause. Curr Opin Infect Dis 21: 271-278.
16. Imitola J, Chitnis T, Khoury SJ 2005. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 106: 163-177.
17. Ishigami T, White CA, Pender MP 1998. Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. Eur J Immunol 28: 1626-1635.
18. + suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-beta. J Immunol 146: 1163-1168.
19. Kieseier BC, Hartung HP 2003. Multipleparadigm shifts in multiple sclerosis. Curr Opin Neurol 16: 247-252.
20. Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G, Thompson EJ, Giovannoni G 2005. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 11: 492-494.
21. Man S, Ubogu EE, Ransohoff RM 2007. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol 17: 243-250.
22. Martin R, McFarland HF 1995. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 32: 121-182.
23. McGeachy MJ, Anderton SM 2005. Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 32: 81-84.
24. Merril JE, Benveniste EM 1996. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci 19: 331-338.
25. Mustafa MI, Diener P, Höjeberg B, van der Meide P, Olsson T 1991. T cell immunity and interferon-γ secretion during experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 31: 165-177.
26. Raine CS 1984. Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab Invest 50: 608-635.
27. Ruddle NH, Bergman CM, McGrath ML, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 172: 1193-1200.
28. Selmaj K, Raines CS, Cross AH 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30: 694-700.
29. Stanislaus R, Pahan K, Singh AK, Singh I 1999. Amelioration of experimental allergic encephalomyelitis in Lewis rats by Lovastatin. Neurosci Lett 269: 71-74.
30. Stanislaus R, Singh AK, Singh I 2001. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 66: 155-162.
31. Stevens DB, Gould KE, Swanborg RH 1994. Transforming growth factor-β1 inhibits tumor necrosis factor-TNF-α/lymphotoxin production and adoptive transfer of disease by effector cells of auto-immune encephalomyelitis. J Neuroimmunol 51: 77-83.
32. Swanborg RH 2001. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactive. Immunol Rev 184: 129-135.
33. + encephalitogenic T cells. Eur J Immunol 24: 2609-2617.
34. Tran EH, Prince EN, Owens T 2000. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 164: 2759-2768.
35. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK, BioMS Study Group 2009. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35: 117-127.
36. Waxman FJ, Fritz RB, Hinrichs DJ 1980. The presence of specific antigen-reactive cells during the induction, recovery and resistance phases of experimental allergic encephalomyelitis. Cell Immunol 49: 34-42.
37. Welch AM, Holda JH, Swanborg RH 1980. Regulation of experimental allergic encephalomyelitis. II. Appearance of suppressor cells during the remission phase of the disease. J Immunol 125: 186-189.
38. Yu P, Gregg RK, Bell JJ, Ellis JS, Divekar R, Lee HH, Jain R, Waldner H, Hardaway JC, Collins M, Kuchroo VK, Zaghouani H 2005. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol 174: 6772-6780.
39. Ziemssen T, Ziemssen F 2005. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental auto-immune encephalomyelitis (EAE). Autoimmun Rev 4: 460-467.